AR046510A1 - Composicion de un antagonista de vegf y un agente anti-proliferativo - Google Patents
Composicion de un antagonista de vegf y un agente anti-proliferativoInfo
- Publication number
- AR046510A1 AR046510A1 ARP040102585A ARP040102585A AR046510A1 AR 046510 A1 AR046510 A1 AR 046510A1 AR P040102585 A ARP040102585 A AR P040102585A AR P040102585 A ARP040102585 A AR P040102585A AR 046510 A1 AR046510 A1 AR 046510A1
- Authority
- AR
- Argentina
- Prior art keywords
- vegf
- proliferative agent
- composition
- agent
- vegf antagonist
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 6
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 5
- 239000005022 packaging material Substances 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 abstract 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49000203P | 2003-07-25 | 2003-07-25 | |
| US49397103P | 2003-08-08 | 2003-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046510A1 true AR046510A1 (es) | 2005-12-14 |
Family
ID=34118812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102585A AR046510A1 (es) | 2003-07-25 | 2004-07-21 | Composicion de un antagonista de vegf y un agente anti-proliferativo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7354579B2 (enExample) |
| EP (1) | EP1648428A2 (enExample) |
| JP (1) | JP5355856B2 (enExample) |
| KR (1) | KR101175990B1 (enExample) |
| AR (1) | AR046510A1 (enExample) |
| AU (1) | AU2004261165C1 (enExample) |
| BR (1) | BRPI0412798A (enExample) |
| CA (1) | CA2529742C (enExample) |
| IL (1) | IL172406A (enExample) |
| MX (1) | MXPA05013642A (enExample) |
| MY (1) | MY149169A (enExample) |
| NO (1) | NO20060924L (enExample) |
| NZ (1) | NZ544570A (enExample) |
| RU (1) | RU2353353C2 (enExample) |
| TW (1) | TWI351953B (enExample) |
| UY (1) | UY28438A1 (enExample) |
| WO (1) | WO2005011734A2 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2003002609A2 (en) * | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| AU2003290330A1 (en) * | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US7354578B2 (en) * | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
| FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
| AU2006213856B2 (en) * | 2005-02-11 | 2011-03-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent |
| CA2598239C (en) * | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN102614134B (zh) * | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
| ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| EP2338488A1 (en) * | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| RU2432155C3 (ru) * | 2006-06-16 | 2017-11-17 | Ридженерон Фармасьютикалз, Инк. | Составы антагониста vegf, подходящие для интравитреального введения |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| EP2125002A4 (en) * | 2007-03-14 | 2011-02-23 | Mayo Foundation | TREATMENT OF SKIN CANCER |
| EA200901301A1 (ru) * | 2007-06-06 | 2010-06-30 | Домантис Лимитед | Полипептиды, вариабельные домены антител и антагонисты |
| FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| LT5610B (lt) | 2007-12-17 | 2009-11-25 | Uab Baltec Cnc Technologies, , | Kompleksinė sveikatinimo ir sporto įrangos sistema ir jos įgyvendinimo būdas |
| SI2310011T1 (sl) * | 2008-06-17 | 2013-10-30 | Wyeth Llc | Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin |
| WO2010005527A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
| EP3266453A1 (en) | 2008-07-03 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Treating cancer |
| MY160399A (en) | 2009-07-06 | 2017-03-15 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| ES2600912T3 (es) | 2010-03-29 | 2017-02-13 | Abraxis Bioscience, Llc | Métodos para tratar el cáncer |
| WO2011153010A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Biosciences, Llc | Methods of treatment of pancreatic cancer |
| MX385629B (es) | 2011-01-13 | 2025-03-18 | Regeneron Pharma | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| EP2717884A1 (en) | 2011-06-06 | 2014-04-16 | Chevron Phillips Chemical Company LP | Use of metallocene compounds for cancer treatment |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| TW202204596A (zh) | 2014-06-06 | 2022-02-01 | 美商健臻公司 | 灌注培養方法及其用途 |
| JP6695286B2 (ja) | 2014-06-13 | 2020-05-20 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | リンパ腫の処置 |
| JP6600651B2 (ja) | 2014-06-16 | 2019-10-30 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 骨髄腫の治療 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| MY194736A (en) | 2015-09-23 | 2022-12-15 | Aerpio Therapeutics Inc | Methods of treating intraocular pressure with activators of tie-2 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| CA3012718A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| EP3432926A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| US11059885B2 (en) | 2016-05-13 | 2021-07-13 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
| US10654922B2 (en) * | 2016-05-13 | 2020-05-19 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| US11548946B2 (en) | 2016-09-01 | 2023-01-10 | Mayo Foundation For Medical Education And Research | Carrier-PD-L1 binding agent compositions for treating cancers |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| KR20230011473A (ko) | 2016-09-06 | 2023-01-20 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Ｐｄ－ｌ１ 발현 암의 치료 방법 |
| KR20230010817A (ko) | 2016-09-06 | 2023-01-19 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법 |
| JP2020510673A (ja) | 2017-03-03 | 2020-04-09 | ヤンセン バイオテツク，インコーポレーテツド | がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法 |
| SMT202200374T1 (it) | 2017-11-30 | 2022-11-18 | Regeneron Pharma | Uso di un antagonista del vegf per trattare disturbi angiogenici dell’occhio |
| ES3009668T3 (en) | 2018-01-26 | 2025-03-31 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| KR20210021299A (ko) | 2018-05-10 | 2021-02-25 | 리제너론 파아마슈티컬스, 인크. | 고농도 vegf 수용체 융합 단백질 함유 제제 |
| US11253502B2 (en) | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| EP4065150A4 (en) | 2019-11-25 | 2023-12-06 | The Regents of the University of California | LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| TW202313095A (zh) | 2021-05-17 | 2023-04-01 | 美商再生元醫藥公司 | 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案 |
| TW202400214A (zh) | 2022-03-15 | 2024-01-01 | 美商再生元醫藥公司 | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 |
| AU2023234355A1 (en) | 2022-03-15 | 2024-09-19 | Bayer Healthcare Llc | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
| US20250025531A1 (en) | 2023-06-23 | 2025-01-23 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
| WO2025217334A1 (en) | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| WO2000064946A2 (en) * | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| CA2376379C (en) * | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7354578B2 (en) * | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
-
2004
- 2004-07-21 AR ARP040102585A patent/AR046510A1/es unknown
- 2004-07-23 KR KR1020067000521A patent/KR101175990B1/ko not_active Expired - Lifetime
- 2004-07-23 BR BRPI0412798-6A patent/BRPI0412798A/pt not_active Application Discontinuation
- 2004-07-23 MY MYPI20042968A patent/MY149169A/en unknown
- 2004-07-23 CA CA2529742A patent/CA2529742C/en not_active Expired - Lifetime
- 2004-07-23 NZ NZ544570A patent/NZ544570A/en not_active IP Right Cessation
- 2004-07-23 MX MXPA05013642A patent/MXPA05013642A/es not_active Application Discontinuation
- 2004-07-23 EP EP04779050A patent/EP1648428A2/en not_active Withdrawn
- 2004-07-23 WO PCT/US2004/023815 patent/WO2005011734A2/en not_active Ceased
- 2004-07-23 RU RU2006105496/15A patent/RU2353353C2/ru active
- 2004-07-23 TW TW093121978A patent/TWI351953B/zh not_active IP Right Cessation
- 2004-07-23 JP JP2006521281A patent/JP5355856B2/ja not_active Expired - Lifetime
- 2004-07-23 AU AU2004261165A patent/AU2004261165C1/en not_active Expired
- 2004-07-23 US US10/897,802 patent/US7354579B2/en not_active Expired - Lifetime
- 2004-07-26 UY UY28438A patent/UY28438A1/es not_active Application Discontinuation
-
2005
- 2005-12-06 IL IL172406A patent/IL172406A/en not_active IP Right Cessation
-
2006
- 2006-02-24 NO NO20060924A patent/NO20060924L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007500131A (ja) | 2007-01-11 |
| JP5355856B2 (ja) | 2013-11-27 |
| MXPA05013642A (es) | 2006-03-10 |
| UY28438A1 (es) | 2004-11-08 |
| IL172406A (en) | 2016-04-21 |
| NZ544570A (en) | 2008-08-29 |
| WO2005011734A2 (en) | 2005-02-10 |
| US7354579B2 (en) | 2008-04-08 |
| CA2529742C (en) | 2012-09-18 |
| RU2353353C2 (ru) | 2009-04-27 |
| RU2006105496A (ru) | 2006-06-10 |
| BRPI0412798A (pt) | 2006-09-26 |
| EP1648428A2 (en) | 2006-04-26 |
| MY149169A (en) | 2013-07-31 |
| AU2004261165C1 (en) | 2009-12-17 |
| AU2004261165B2 (en) | 2009-07-16 |
| AU2004261165A1 (en) | 2005-02-10 |
| NO20060924L (no) | 2006-04-25 |
| CA2529742A1 (en) | 2005-02-10 |
| TWI351953B (en) | 2011-11-11 |
| WO2005011734A3 (en) | 2005-04-14 |
| US20050032699A1 (en) | 2005-02-10 |
| KR101175990B1 (ko) | 2012-08-23 |
| TW200524589A (en) | 2005-08-01 |
| IL172406A0 (en) | 2006-04-10 |
| KR20060028654A (ko) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046510A1 (es) | Composicion de un antagonista de vegf y un agente anti-proliferativo | |
| AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
| PE20081297A1 (es) | Forma de dosificacion transdermica resistente a la manipulacion | |
| CL2010001358A1 (es) | Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina. | |
| UY28213A1 (es) | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. | |
| CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
| UY26296A1 (es) | Tratamiento medicamentoso del síndrome de piernas inquietas | |
| CL2008002224A1 (es) | Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer. | |
| EA200501586A1 (ru) | Фармацевтические продукты | |
| ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
| CO6251236A2 (es) | Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico | |
| AR091967A1 (es) | Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept | |
| ECSP034868A (es) | Cápsulas para inhalación | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| AR112103A1 (es) | Compuestos para el tratamiento de tnbc | |
| SV2002000969A (es) | Composicion parenteral reconstituible | |
| CL2008003699A1 (es) | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. | |
| ES2530731T3 (es) | Dispositivos médicos que contienen nitroprusiato y agentes antimicrobianos | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
| AR048050A1 (es) | Formas de administracion masticables, no comprimidas, dosificadas individualmente | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
| AR085132A1 (es) | Composiciones farmaceuticas para el tratamiento de glioma maligno | |
| AR066778A1 (es) | Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |